drugset
drugset / Trial / NCT05555758

Aom0319 SAD Study in Healthy Subjects

NCT05555758 ↗

Phase 1 Completed 38 enrolled Amckaus PTY LTD.
RandomizedSequentialQuadruple-blindTreatment

Summary

Only SAD study will be conducted in this project. SAD represents single ascending dose. Multiple ascending dose have been cancelled. This decision has been made at the discretion of the Sponsor.

Timeline

Start
2022-12-15
Primary completion
2023-12-13
Completion
2023-12-21

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adamgammadex Sodium Unknown — Intravenous

Indications

No indication recorded.